Overview

A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

This study will examine the effect of an inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A4) and permeability glycoprotein 1 (P gp) (200 mg itraconazole) on the PK disposition of a 10 mg tablet of TD- 1211 administered orally to fasted subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Theravance Biopharma
Theravance Biopharma R & D, Inc.

Treatments:

Hydroxyitraconazole
Itraconazole
Krestin